ClinicalTrials.gg
RecruitingNCT07024836PRAGMATIC-DCEUpdated Jun 17, 2025

PRecision biomArker-Guided MAnagement of TuberculosIs Contacts: a Discrete Choice Experiment

An observational study in Tuberculosis (TB), sponsored by University College, London. Recruiting at 1 site in United Kingdom. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2025-06-17.

Sponsored by University College, London · Observational

How we know

From the registry’s dates

  • Started May 2025; still recruiting 1 year 5 months later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Study type
Observational
Model
Cohort
Time perspective
Cross-sectional
Enrollment
430
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-21

Among 66 studies in Tuberculosis with a site in United Kingdom — 8 open to participants now, 10 under way, none of them phase 3. Tuberculosis · United Kingdom.

Planned enrollment
7th of 20
430 · median 225
Started
2025
with 2 others
Observational
20 of 66
7 open now
Registered
63rd of 66
by date
Lead sponsor
3 of 66
University College, London

Among the 66 studies in Tuberculosis with a site in United Kingdom, this one is the 7th largest by planned enrollment of the 20 observational ones that give a count, is one of 3 that started in 2025, is one of 20 observational ones, and was the 63rd registered.

Tuberculosis

1,173 studies on the registry are indexed under Tuberculosis; 177 are open to participants now.

Browse Tuberculosis studies →

Open to participants now

8 of the 66 studies in Tuberculosis with a site in United Kingdom are open now. Recruiting first, the newest first:

2 more — sign in →

All 8 open studies →

A study can be open while its sites in United Kingdom have not opened yet or have stopped. Only those recruiting at a site in United Kingdom →

Who these studies take

Of the 112 Tuberculosis studies recruiting now, 65 (58%) set no upper age limit and 37 (33%) stop at 75 or younger; 49 take children under 18; 31 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 66 studies in Tuberculosis with a site in United Kingdom, or all of them as a file.
02

Study summary

This study is part of a broader programme of work to develop and pilot a randomised-controlled trial of new tests to identify people who will benefit most from preventive treatment for tuberculosis (TB). The aim of the current study is to explore factors affecting patient decisions to start preventive treatment. The specific objectives are to understand how patients make decisions about preventive treatment initiation for TB (stage 1); and to design and conduct a "discrete choice experiment" survey to further evaluate preferences (stage 2).

Read the detailed description

We will perform up to 30 semi-structured interviews among people undergoing testing for latent TB infection, as part of routine clinical screening programmes (stage 1). Adults (aged ≥18 years) who have been or are being tested for LTBI in routine clinical services will be eligible for inclusion through purposive sampling. The findings from the qualitative study will then be used to inform the a discrete choice experiment (DCE). The DCE will be conducted to quantify the trade-off between future TB risk and preventive treatment acceptance, from patient and healthcare provided perspectives (stage 2).

03

Conditions studied

  • Tuberculosis (TB)

Keywords

  • preference
  • discrete choice experiment
  • qualitative
  • latent tuberculosis infection
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No
Sampling method
Non-probability sample

Study population

  1. Adults tested, or eligible for testing, for latent tuberculosis infection in routine clinical services.
  2. Nurses, doctors or allied health professionals who have any experience of testing or treatment for TB or latent TB infection in UK services.

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Adults (aged ≥18 years) who have been tested for latent TB infection in routine clinical services, or are eligible for testing. Eligible people for testing include migrants from countries with high TB incidence (entered UK within 5 years), people with recent contact with a person with TB disease, and people eligible for LTBI screening prior to starting or through occupational health testing.

Exclusion criteria

Exclusion Criteria:

  • Unable to provide .
Terms in these criteria, in plain language(2)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Immunosuppression

A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.

Read whether the line is about a condition or about medicines, and which medicines and doses it means.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

05

Study design

Observational model
Cohort
Time perspective
Cross-sectional
Enrollment
430 participants (estimated)
Patient registry
No

Groups and cohorts

  • Patient participants for qualitative stage (stage 1)

    Semi-structured interviews will first be conducted among 20-30 people undergoing testing for latent tuberculosis infection, as part of routine clinical screening programmes (Stage 1).

  • Patient participants for discrete choice experiment (stage 2)

    200 patients will then undertake a quantitative discrete choice experiment to evaluate preferences and trade-offs that influence acceptance of preventive TB treatment.

  • Healthcare worker participants for discrete choice experiment (stage 2)

    200 healthcare workers will also undertake a quantitative discrete choice experiment to evaluate preferences and trade-offs that influence recommendation of preventive TB treatment.

06

What researchers measure

Primary outcomes

  1. Preventive treatment acceptance

    Discrete choice experiment data will be analysed to evaluate the primary outcome of preventive TB treatment acceptance in the survey.

    Time frame: Baseline

07

Study locations

1 of 1 sites recruiting
08

References and documents

Individual participant data

Plan to share: Yes — Anonymised data from the discrete choice experiment will be made publicly available at the time of peer-reviewed publication.

Time frame: Indefinitely from the time of peer-reviewed publication.

Access criteria: The anonymised discrete choice experiment data will be publicly available

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Started May 2025 (actual). Primary completion is estimated for Dec 2026, 19 months after the start.

How these figures are worked out, and which studies are left out of them.

Registered
May 16, 2025
First posted
Jun 17, 2025
StartActual
May 22, 2025
Primary completionEst.
Dec 2026
CompletionEst.
Dec 2026
Last update
Jun 17, 2025
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jun 17, 2025, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT07024836
Responsible party
Sponsor
First posted
Jun 17, 2025
Start date
May 22, 2025
Primary completion
Dec 2026 (estimated)
Completion
Dec 2026 (estimated)
Last update
Jun 17, 2025

Study contacts

Rishi K Gupta, PhD
Contact
r.gupta@ucl.ac.uk
020 3549 5979

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion